Skip to main content

Table 2 Siglec-directed therapeutics for tumor

From: The intriguing roles of Siglec family members in the tumor microenvironment

Siglec Drug Tumor type Modality Therapeutic strategy Phase Refs/Trial ID
Siglec-2 (CD22) Epratuzumab B cell lymphoma MoAb Inhibits the cis SA-Siglec-2 interaction for the induction of B cell signal transduction and caspase-dependent apoptosis II NCT00906841
Inotuzumab ozogamicin B cell lymphoma MoAb Causes cell death by inducing double-strand DNA breaks I/II NCT01363297 NCT01564784
DT2219 Refractory B-lineage leukemia or lymphoma BsAb Inhibits the protein synthesis and apoptosis I/II NCT02370160
CD22-CAR-T Follicular lymphoma, ALL, NHL, Large cell lymphoma CAR T Recognises specific antibodies from tumour cells and targets them I NCT02315612
Siglec-3 (CD33) lintuzumab AML MoAb Induces cell death by complement and/or antibody-directed cellular cytotoxicity or as a direct effect of engaging the CD33 receptor I/II NCT03441048 NCT03867682
Gentuzumab Ozogamicin Newly diagnosed and relapsed AML MoAb Leads to cell death by causing site-specific, double-stranded breaks II NCT03374332
AMG330 AML BiTE Directs cytotoxic T cells to CD33-expressed human AML cells killing the target I NCT02520427
JNJ-67571244 Not responding AML patients at high risk of myelodysplastic syndrome BiTE Directs cytotoxic T cells to CD33-expressed human AML cells killing the target I NCT03915379
CD33 CAR-T AML CAR T T-cells are genetically changed to help target leukemia cells I/II NCT03126864
Siglec 6 Siglec-6 CAR-T CLL CAR T Increases the activity of CARs that target membrane-distal epitopes Not Applicable [23]
Siglec 7 Ganglioside GD3 Melanoma Vaccine Modulate NK cell cytotoxicity Not Applicable NCT00597272
Siglec-7 CAR-T Solid Tumors CAR T Recognizes and eliminates tumor cells, in a non‐ histocompatibility complex molecule restricted way Not Applicable [74]
Siglec 9 Gatipotuzumab Solid Tumors MoAb Activats the immune system to induce ADCC agains tumor cells I/II NCT01222624 NCT03360734
Siglec-9 CAR-T Solid Tumors CAR T Recognizes and eliminates tumor cells, in a non‐ histocompatibility complex molecule restricted way Not Applicable [74]
Siglec 10 Alemtuzumab CLL MoAb Kills of tumour cells by CDC and ADCC II NCT01465334
Siglec 15 NC318 Advanced or metastatic solid tumors MoAb Restores normal T-cell function by blocking Siglec-15-mediated immunosuppression I/II NCT03665285
  1. AML Acute myeloid leukemia, ALL Acute lymphoblastic leukemia, NHL Non-Hodgkin’s lymphoma, CLL Chronic lymphocytic leukemia, CART Chimeric antigen receptor-T cells, MoAb: Monoclonal antibody, BsAb Bispecific monoclonal antibody